Rise Advisors’s Emergent Biosolutions EBS Stock Holding History

Rise Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-207	Closed	-$1.01K	–	1577
2025 Q1	$1.01K	Buy	+207	New	+$1.71K	﹤0.01%	1257

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rise Advisors's EBS Position: Q2 2025 in Review

Rise Advisors sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 207 shares — an estimated $1.01K sold.

Rise Advisors first reported a position in EBS in Q1 2025 and held it in 1 quarter. The position peaked at $1.01K in Q1 2025. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

Rise Advisors reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
Rise Advisors sold 207 Emergent Biosolutions shares in Q2 2025, an estimated $1.01K.
Rise Advisors first reported a position in Emergent Biosolutions in Q1 2025 and held it in 1 quarter.
Rise Advisors's Emergent Biosolutions position peaked at $1.01K in Q1 2025.
161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on Rise Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.